- Home
- ANAB vs CAC Comparison
ANAB vs CAC Comparison
Compare ANAB & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CAC
- Stock Information
- Founded
- ANAB 2005
- CAC 1875
- Country
- ANAB United States
- CAC United States
- Employees
- ANAB N/A
- CAC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- ANAB Health Care
- CAC Finance
- Exchange
- ANAB Nasdaq
- CAC Nasdaq
- Market Cap
- ANAB 621.1M
- CAC 629.3M
- IPO Year
- ANAB 2017
- CAC 1997
- Fundamental
- Price
- ANAB $20.14
- CAC $38.72
- Analyst Decision
- ANAB Buy
- CAC Buy
- Analyst Count
- ANAB 10
- CAC 3
- Target Price
- ANAB $48.00
- CAC $48.00
- AVG Volume (30 Days)
- ANAB 500.2K
- CAC 77.4K
- Earning Date
- ANAB 08-06-2025
- CAC 07-29-2025
- Dividend Yield
- ANAB N/A
- CAC 4.26%
- EPS Growth
- ANAB N/A
- CAC 4.80
- EPS
- ANAB N/A
- CAC 3.11
- Revenue
- ANAB $123,164,000.00
- CAC $197,501,000.00
- Revenue This Year
- ANAB N/A
- CAC $40.83
- Revenue Next Year
- ANAB $24.39
- CAC $5.29
- P/E Ratio
- ANAB N/A
- CAC $12.67
- Revenue Growth
- ANAB 304.17
- CAC 21.74
- 52 Week Low
- ANAB $12.21
- CAC $34.53
- 52 Week High
- ANAB $40.70
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- ANAB 31.39
- CAC 46.96
- Support Level
- ANAB $19.55
- CAC $36.61
- Resistance Level
- ANAB $22.03
- CAC $39.95
- Average True Range (ATR)
- ANAB 1.50
- CAC 1.31
- MACD
- ANAB -0.53
- CAC 0.20
- Stochastic Oscillator
- ANAB 12.05
- CAC 49.90
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.